answer from hershel, page-2

"leveraging the commercial assets to enable the ability to add late stage programs, and operating a streamlined organization seems to me like a very rational approach to achieve growth."

-----

This has got me puzzled. We don't have enough money to fund Vapendavir through Phase III, let alone add more late stage candidates to the pipeline.

Why they are even contemplating adding late stage compounds through acquisition is beyond me.

110% of the company's focus should be pushing Vapendavir forward as fast as humanly possible...there's enough literature out there suggesting there is a worthwhile market...although a lack of a deal might mean otherwise.

This is our growth opportunity and we don't have to wait 10 years for it...this could be on the market before LANI.

A virgin market and for now we are in the lead. This is RP's opportunity to create wealth.